Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04508647
Title Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver

marginal zone B-cell lymphoma

follicular lymphoma



Ublituximab + Umbralisib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.